About Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas. This segments principal products include Amoclan, Blopress, Omnicef, Prograf, and Suprax. The Injectables segment markets 201 products in 571 dosage strengths and forms for anti-infective, cardiovascular, diabetes, controlled substances, gastro-intestinal, oncology, CNS, respiratory, and miscellaneous therapeutic areas. This segment also offers sterile liquid, powder, lyophilized, and cytotoxic products. This segments principal products include fentanyl, glycopyrrolate, neostigmine, nicardipine, and thiotepa. The Generics segment provides 109 products in 375 dosage strengths and forms for therapeutic areas, including anti-infective, controlled substances, oncology, and miscellaneous therapeutic areas. This segments principal products include amoxicillin, buprenorphine, butalbital, acetaminophen and caffeine, colchicine, and fluticasone. This segment markets its products to chain stores, wholesalers, distributors, health systems, and governmental agencies in the form of tablets, capsules, solutions, and suspensions. In addition, the company manufactures plastic specialized medicinal sterile containers and APIs; and conducts bio-equivalency studies. Hikma Pharmaceuticals PLC was founded in 1978 and is based in London, the United Kingdom.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:HKMPF
- Previous Symbol: OTC:HKMPF
- CUSIP: N/A
- Web: www.hikma.com
Sales & Book Value:
- Forward P/E Ratio: 13.33
- P/E Growth: 1.76
- Annual Sales: $1.95 billion
- Price / Sales: 1.53
- Book Value: N/A
- Price / Book: N/A
- Annual Dividend: $0.22
- Dividend Yield: 2.6%
- Employees: 8,500
- Outstanding Shares: 240,660,000
Frequently Asked Questions for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
What is Hikma Pharmaceuticals Plc's stock symbol?
Hikma Pharmaceuticals Plc trades on the OTCMKTS under the ticker symbol "HKMPF."
Who are some of Hikma Pharmaceuticals Plc's key competitors?
Some companies that are related to Hikma Pharmaceuticals Plc include Grifols, S.A. (GRFS), Stada Arzneimi (STDAF), Olympus Corp. (OCPNY), HealthSouth Corporation (HLS), Gn Store Nord (GNNDY), Orion OYJ Unsponsored ADR (ORINY), Swedish Orphan (SWTUY), Chemed Corp. (CHE), Btg Plc (BTGGF), Indivior PLC (INVVY), Envision Healthcare Corporation (EVHC), Sartorius Ag (SARTF), Elekta AB (EKTAY), Udg Healthcare (UDHCF), Abcam PLC Unsponsored ADR (ABCZY), Evotec AG (EVTCY), China Biologic Products (CBPO) and AnaptysBio (ANAB).
How do I buy Hikma Pharmaceuticals Plc stock?
Shares of Hikma Pharmaceuticals Plc can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Hikma Pharmaceuticals Plc's stock price today?
One share of Hikma Pharmaceuticals Plc stock can currently be purchased for approximately $12.40.
How big of a company is Hikma Pharmaceuticals Plc?
Hikma Pharmaceuticals Plc has a market capitalization of $2.98 billion and generates $1.95 billion in revenue each year. Hikma Pharmaceuticals Plc employs 8,500 workers across the globe.
How can I contact Hikma Pharmaceuticals Plc?
Hikma Pharmaceuticals Plc's mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 44-20-7399-2760 or via email at [email protected]
MarketBeat Community Rating for Hikma Pharmaceuticals Plc (OTCMKTS HKMPF)MarketBeat's community ratings are surveys of what our community members think about Hikma Pharmaceuticals Plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 4 Hold Ratings, 0 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Hold (Score: 2.00)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
Analysts' Ratings History for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
(Data available from 11/18/2015 forward)
|8/22/2017||The Goldman Sachs Group, Inc.||Downgrade||Buy -> Neutral|
|8/21/2017||Jefferies Group LLC||Upgrade||Underperform -> Hold|
|8/8/2017||Morgan Stanley||Reiterated Rating||Equal Weight|
|5/19/2017||Numis Securities Ltd||Reiterated Rating||Buy -> Add|
Earnings History for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
Current Year EPS Consensus Estimate: $0.93 EPS
Next Year EPS Consensus Estimate: $1 EPS
Dividend History for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Hikma Pharmaceuticals Plc (OTCMKTS HKMPF)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)
Latest Headlines for Hikma Pharmaceuticals Plc (OTCMKTS HKMPF)
No headlines for this company have been tracked by MarketBeat.com
Financials are not available for this stock.
Hikma Pharmaceuticals Plc (OTCMKTS HKMPF) Chart for Saturday, November, 18, 2017